David Meek, the CEO of biopharmaceutical company Ipsen, will resign from his post Dec. 31 to lead a new gene therapy startup, FerGene, according to EndPoints News.
FerGene was launched in November by Ferring Pharmaceuticals and Blackstone Life Sciences. He will take over as CEO on Jan. 14.
The board of Ipsen has named Aymeric Le Chatelier, currently CFO, as interim CEO to replace Mr. Meek until a permanent CEO is found.
"It has been my honor to work with the great team at Ipsen," Mr. Meek said. "I am proud of the accomplishments we have achieved together to be one of the fastest-growing companies in our industry."
More articles on pharmacy:
Humana to buy hospice pharmacy Enclara Healthcare
Kite Pharma ordered to pay Juno Therapeutics $752M in CAR-T drug infringement case
Walgreens is Dow's worst-performing stock of 2019